The treatment of alcohol use disorder (AUD) with sodium oxybate (SMO) or gamma-hydroxybutyric acid (GHB) was introduced in Italy and Austria more than 20 years and 15 years ago, respectively, and it is now widely employed to treat alcohol withdrawal syndrome (AWS) and to maintain alcohol abstinence. These indications derive from its similar structure to the inhibitory neurotransmitter γ-amino-butyric acid (GABA), exerting an ethanol-mimicking effect, because it binds to GABAB receptors. Craving for, and abuse of, SMO remain a controversial issue; even though these unfavorable effects are evident in poly-drug addicted patients and in those with psychiatric diagnosis of borderline personality disorder. In addition, despite cases of severe intoxication and deaths being widely documented when GHB is used as "street drug"; its clinical use remains safe. Thus, the aim of the present review is to examine the role of SMO in the treatment of AUD, its possible implications in reducing alcohol consumption, and cases of abuse, and severe intoxication due to SMO during its clinical use in the treatment of AUD.

A brief up-date of the use of sodium exybate for the treatment of alcohol use disorders / Caputo, F.; Vignoli, T; Tarli, C; Domenicali, M; Zoli, G; Bernardi, M; Addolorato, G. - In: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. - ISSN 1660-4601. - ELETTRONICO. - 13:(2016), pp. E290.1-E290.6. [10.3390/ijerph13030290]

A brief up-date of the use of sodium exybate for the treatment of alcohol use disorders.

DOMENICALI, MARCO;BERNARDI, MAURO;
2016

Abstract

The treatment of alcohol use disorder (AUD) with sodium oxybate (SMO) or gamma-hydroxybutyric acid (GHB) was introduced in Italy and Austria more than 20 years and 15 years ago, respectively, and it is now widely employed to treat alcohol withdrawal syndrome (AWS) and to maintain alcohol abstinence. These indications derive from its similar structure to the inhibitory neurotransmitter γ-amino-butyric acid (GABA), exerting an ethanol-mimicking effect, because it binds to GABAB receptors. Craving for, and abuse of, SMO remain a controversial issue; even though these unfavorable effects are evident in poly-drug addicted patients and in those with psychiatric diagnosis of borderline personality disorder. In addition, despite cases of severe intoxication and deaths being widely documented when GHB is used as "street drug"; its clinical use remains safe. Thus, the aim of the present review is to examine the role of SMO in the treatment of AUD, its possible implications in reducing alcohol consumption, and cases of abuse, and severe intoxication due to SMO during its clinical use in the treatment of AUD.
2016
A brief up-date of the use of sodium exybate for the treatment of alcohol use disorders / Caputo, F.; Vignoli, T; Tarli, C; Domenicali, M; Zoli, G; Bernardi, M; Addolorato, G. - In: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. - ISSN 1660-4601. - ELETTRONICO. - 13:(2016), pp. E290.1-E290.6. [10.3390/ijerph13030290]
Caputo, F.; Vignoli, T; Tarli, C; Domenicali, M; Zoli, G; Bernardi, M; Addolorato, G
File in questo prodotto:
File Dimensione Formato  
GHB update.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 261.18 kB
Formato Adobe PDF
261.18 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/561695
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact